FDA panel to review NSAIDs this month

Share this article:

An FDA advisory panel convenes in six days to consider revoking the over-the-counter status of some NSAIDs. Drugstore News reports that the group will meet February 10 to discuss the risks these drugs may pose to heart health. DSN says the group will also discuss whether Pfizer should continue its Celebrex safety study which compares the arthritis pain reliever to ibuprofen and naproxen, since naproxen is considered safer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.